KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $892.5 million.

  • Halozyme Therapeutics' Non-Current Assets fell 994.61% to $892.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 486.69%. This contributed to the annual value of $978.1 million for FY2024, which is 88.25% down from last year.
  • Halozyme Therapeutics' Non-Current Assets amounted to $892.5 million in Q3 2025, which was down 994.61% from $931.2 million recorded in Q2 2025.
  • Halozyme Therapeutics' Non-Current Assets' 5-year high stood at $1.2 billion during Q2 2022, with a 5-year trough of $24.9 million in Q1 2021.
  • In the last 5 years, Halozyme Therapeutics' Non-Current Assets had a median value of $978.1 million in 2024 and averaged $785.8 million.
  • In the last 5 years, Halozyme Therapeutics' Non-Current Assets skyrocketed by 464649.41% in 2022 and then crashed by 1631.96% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Non-Current Assets (Quarter) stood at $178.1 million in 2021, then skyrocketed by 518.89% to $1.1 billion in 2022, then dropped by 10.49% to $986.8 million in 2023, then fell by 0.88% to $978.1 million in 2024, then decreased by 8.76% to $892.5 million in 2025.
  • Its Non-Current Assets stands at $892.5 million for Q3 2025, versus $931.2 million for Q2 2025 and $934.5 million for Q1 2025.